Liu M, Counsell C, Sandercock P
Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
Cochrane Database Syst Rev. 2000(2):CD000248. doi: 10.1002/14651858.CD000248.
After a first stroke, further vascular events (especially myocardial infarction and recurrent stroke) are common and often fatal.
The objective of this review was to assess the effect of prolonged anticoagulant therapy following presumed non-embolic ischaemic stroke or transient ischaemic attack.
We searched the Cochrane Stroke Group trials register. We contacted companies marketing anticoagulant agents.
Randomised and quasi-randomised trials comparing anticoagulant therapy, for at least one month, with control in people with previous non-embolic presumed ischaemic stroke or transient ischaemic attack.
Two reviewers independently selected trials for inclusion, assessed trial quality and extracted the data.
Nine trials involving 1214 patients were included. The quality of all trials was poor. All pre-dated routine computerised tomography scanning and use of the International Normalised Ratio to monitor anticoagulation. Anticoagulant therapy did not significantly reduce the odds of death or dependency (two trials, odds ratio 0.83, 95% confidence interval 0.52 to 1.34). Death from any cause (odds ratio 0.95, 95% confidence interval 0.72 to 1.23), and death from vascular causes (odds ratio 0.86, 95% confidence interval 0.66 to 1.13) were not significantly different between treatment and control across all nine trials. Anticoagulant therapy did not reduce the risk of recurrent stroke (odds ratio 0.79, 95% confidence interval 0.56 to 1.13). However, fatal intracranial haemorrhage increased (odds ratio 2.54, 95% confidence interval 1.19 to 5.45), as did major extracranial haemorrhage (odds ratio 4.87, 95% confidence interval 2.50 to 9.49). This means anticoagulant therapy caused 11 additional fatal intracranial haemorrhages and 25 additional major extracranial haemorrhages per year for every 1000 patients given anticoagulant therapy.
REVIEWER'S CONCLUSIONS: There appears to be no clear benefit from long-term anticoagulant therapy in people with non-embolic presumed ischaemic stroke or transient ischaemic attack. There appears to be a significant bleeding risk associated with anticoagulant therapy.
首次中风后,进一步的血管事件(尤其是心肌梗死和复发性中风)很常见,且往往是致命的。
本综述的目的是评估在假定为非栓塞性缺血性中风或短暂性脑缺血发作后进行长期抗凝治疗的效果。
我们检索了Cochrane中风小组试验注册库。我们联系了销售抗凝剂的公司。
随机和半随机试验,比较至少为期一个月的抗凝治疗与既往非栓塞性假定缺血性中风或短暂性脑缺血发作患者的对照治疗。
两名评价者独立选择纳入试验、评估试验质量并提取数据。
纳入了9项涉及1214例患者的试验。所有试验质量都很差。所有试验均早于常规计算机断层扫描以及使用国际标准化比值监测抗凝情况。抗凝治疗并未显著降低死亡或依赖的几率(两项试验,比值比0.83,95%置信区间0.52至1.34)。在所有9项试验中,治疗组和对照组之间任何原因导致的死亡(比值比0.95,95%置信区间0.72至1.23)以及血管性原因导致的死亡(比值比0.86,95%置信区间0.66至1.13)均无显著差异。抗凝治疗并未降低复发性中风的风险(比值比0.79,95%置信区间0.56至1.13)。然而,致命性颅内出血增加(比值比2.54,95%置信区间1.19至5.45),颅外大出血也增加(比值比4.87,95%置信区间2.50至9.49)。这意味着每1000例接受抗凝治疗的患者中,抗凝治疗每年会额外导致11例致命性颅内出血和25例颅外大出血。
对于假定为非栓塞性缺血性中风或短暂性脑缺血发作的患者,长期抗凝治疗似乎没有明显益处。抗凝治疗似乎存在显著的出血风险。